Lurbinectedin is a novel anti-tumor agent that has shown promise in the treatment of various types of cancers. Recent studies have suggested that lurbinectedin may have potential benefits when used in combination with immunotherapy.

According to a study published in the Journal of Clinical Oncology [3], lurbinectedin in combination with pembrolizumab (an immune checkpoint inhibitor) showed promising results in patients with advanced solid tumors. The study found that the combination therapy was well-tolerated and resulted in an objective response rate of 33% in patients with non-small cell lung cancer and 20% in patients with small cell lung cancer. The study also noted that the combination therapy resulted in an increase in the number of activated T cells, which are crucial for the immune system's ability to fight cancer cells.

Another study published in the National Center for Biotechnology Information [2] found that lurbinectedin can enhance the anti-tumor activity of T cells by increasing the expression of genes involved in T cell activation. The study also found that lurbinectedin can increase the expression of PD-L1, a protein that is often overexpressed in cancer cells and can suppress the immune system's response to cancer.

Furthermore, a report from Drug Patent Watch [1] suggests that the combination of lurbinectedin and immunotherapy may have the potential to increase the effectiveness of cancer treatment while reducing toxicity and side effects associated with traditional chemotherapy.

In conclusion, the combination of lurbinectedin and immunotherapy has shown promising results in preclinical and clinical studies. The potential benefits of this combination therapy include increased anti-tumor activity, enhanced T cell activation, and reduced toxicity. However, further research is needed to fully understand the potential benefits and risks of this combination therapy in treating various types of cancers.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.TPS8604